Ethics group publishes opinion on nanomedicine

Addressing safety concerns related to advances in the nanomedicine field is of vital importance, according to the newly published "Opinion on the Ethical Aspects of Nanomedicine" from the European Group on Ethics in Science and New Technologies.

The report, which was compiled following a request from European Commission President José Manuel Barroso, recognises the huge potential that nanomedicine offers in terms of developing new diagnostic, treatment and preventive methods.

On safety, the group proposes that measures be established to verify the safety of nanomedical products and devices, and calls on the relevant authorities to carry out a proper assessment of the risks and safety of nanomedicine.

"The Group considers it necessary for appropriate safety research to be carried out and information provided to the public before medical devices and medicinal products derived from nanotechnologies are marketed," states the report, adding that, "the Group considers it paramount that no nano-based products enter the market without risk assessment, thereby securing their safety with regard to users' health."

However, while knowledge gaps remain, researchers should not be afraid of admitting their existence. "Transparency is essential for public trust," the authors write. "This also holds for openness about uncertainties and knowledge gaps."

The group recommends that there should be an EU website on ethics and nanomedicine, where citizens can find information and pose questions to researchers. Furthermore, academic and public debates should be held on the issues raised by forthcoming developments in nanomedicine.

The report also places a strong emphasis on the importance of carrying out more research into the ethical, legal and social implications (ELSI) of nanomedicine. They recommend that up to 3% of the nanotechnology research budget be set aside for ELSI research. They also call on the European Commission to set up a dedicated European Network on Nanotechnology Ethics, financed through the Seventh Framework Programme (FP7). This network would bring together experts from a range of fields, promote deeper understanding of the ethical issues arising from nanotechnology and nanomedicine, promote education in these fields and work to ensure that ethics become embedded in research practices in nanomedicine and nanotechnology.

Looking beyond Europe, the group suggests that the Commission fund a study on the social effects on nanomedicine in developing countries. "Such research should also focus on macroeconomic trends, trade implications and possible international problems, and in particular examine the risk of creating a nano-divide which could widen the gap between the developed and developing countries," the authors write.

On the legal front, the group does not believe that structures set up specifically to deal with nanomedicine are needed right now. However, they suggest monitoring existing regulatory systems to ensure they do address all nanomedical products.

The European Commission spent over €1.36 billion on nanotechnology research under the Sixth Framework Programme. The nanotechnology budget under FP7 is €3.5 billion, and around €100 million per year is expected to be allocated to projects in the field of nanomedicine.

For further information, please visit:
http://ec.europa.eu/european_group_ethics/index_en.htm

Copyright ©European Communities, 2007
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

AI-Powered CRISPR could Lead to Faster G…

Stanford Medicine researchers have developed an artificial intelligence (AI) tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing “copilot” supported by AI to help...

Groundbreaking AI Aims to Speed Lifesavi…

To solve a problem, we have to see it clearly. Whether it’s an infection by a novel virus or memory-stealing plaques forming in the brains of Alzheimer’s patients, visualizing disease processes...

AI Spots Hidden Signs of Depression in S…

Depression is one of the most common mental health challenges, but its early signs are often overlooked. It is often linked to reduced facial expressivity. However, whether mild depression or...

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Tools Help Predict Severe Asthma Risk…

Mayo Clinic researchers have developed artificial intelligence (AI) tools that help identify which children with asthma face the highest risk of serious asthma exacerbation and acute respiratory infections. The study...

AI Model Forecasts Disease Risk Decades …

Imagine a future where your medical history could help predict what health conditions you might face in the next two decades. Researchers have developed a generative AI model that uses...

AI Model Indicates Four out of Ten Breas…

A project at Lund University in Sweden has trained an AI model to identify breast cancer patients who could be spared from axillary surgery. The model analyses previously unutilised information...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...